Noninvasive method for early detection of human cancers is promising way to provide more quality health service to the population. The serum and stool of colorectal cancer patients often harbor increased free DNA levels, which can potentially be used for cancer detection.
Introduction
Colorectal cancer is an important disease with a large morbidity and mortality and increasing health care costs as multi-modality therapy becomes more widespread and new drugs appear. But many of the patients who undergo curative surgical resection will ultimately die of recurrent colorectal cancer, depending mainly on the initial stage of the disease. Thus, earlier detection of colorectal cancer would improve the efficacy of treatment and management of this disease. Therefore, it is vitally important to identify and develop reliable diagnostic markers of early stage colorectal cancer.
Several reports show that tumors can release DNA into the circulation or even into the stool, and these DNAs can be often detectable in the serum and stool of cancer patients. The serum of cancer patients contains, on average, 4~40 times more free DNA, compared with normal individual [1] .
Aberrant WNT pathway signaling is an early progression event in approximately 90% of CRCs and occurs through mutations mainly of APC and, less often, of CTNNB1 (encoding beta-catenin). These mutations allow ligand independent WNT signaling that culminates in abnormal accumulation of free betacatenin in the nucleus [2] [3] [4] . Secreted frizzled-related proteins (SFRPs) possess a domain similar to one in the WNT-receptor frizzled proteins and can inhibit WNT receptor binding to downregulate pathway signaling during development [5] . Recently, gene silencing of SFRPs, which consist of 5 members (SFRP1-5), by the hypermethylation of their promoter was identified in CRCs and other malignancies [6] [7] [8] . Especially, SFRP2 methylation was detected in a high frequency of over 60% of CRCs, including a Lynch syndrome, which suggests that SFRP2 methylation might potentially be useful as a promising sensitive screening marker for the stool-based detection of CRCs and premalignant lesions. We, therefore, investigated macrodissected samples of 117 formalin-fixed and paraffin-embedded colorectal tumor tissues and 68 serum and stool samples from available cases. We also investigated 60 healthy controls in the same way. We proved that serum and stool DNA could be promising marker to detect colorectal cancer in individuals. 
Materials and Methods

Patients
Statistical analysis
One-way analysis, ANOVA with Bonferroni test was used for group comparison. For the statistical analysis, a two-sided value of p<0.05 was considered to indicate statistical significance. Data were analyzed using the SPSS-software 11.5 for windows. 
Results
Frequency of SFRP2 promoter methylation
Correlation with clinical-pathological factors
In our group of colorectal carcinomas, there was no association between SFRP2 promoter methylation and age, gender, histopathological type, tumor stage, grade of differentiation. Detailed information is shown in Table 2 . 
Discussion
Our study clearly demonstrates the biological significance of methylation in the region of the SFRP2 promoter in specimens obtained from the colon and rectum. Aberrant methylation in gene promoters has been established as a key mechanism for the inactivation of tumor suppressor genes in human malignancies, including CRCs. Clinically, the identification of genes that are prone to abnormal methylation and that consequently become downregulated is of critical importance, since this is considered to provide a good source of novel biomarkers. The family of SFRP genes, functionally acting as the WNT signaling inhibitors, was recently shown to be a common target of promoter hypermethylation in numerous tumor entities [9] [10] [11] [12] .
Indeed, we have demonstrated aberrant methylation of the SFRP2 promoter region by analyzing tissue, serum or stool DNA of colorectal cancer patients. This will contribute to the early detection of colorectal cancer in a more quality way.
However, there was no relationship between methylation frequency and clinic-pathological features.
Future study must be on the quantification of methylated CpG islands in the promoter region of this gene and clarify the correlation between methylation level and other clinic-pathological features or survival.
